132IN - Global Cancer Research; current situation and challenges
|Date||01 October 2012|
|Event||ESMO Congress 2012|
|Session||ESMO DCTF-AORTIC-SLACOM-UICC-WHO Joint Symposium: Independent and publicly funded research: a new global model|
|Topics|| Bioethics, Legal, and Economic Issues
Clinical research is vital to the development and improvement of methods to prevent, detect and treat cancer. The majority of clinical trials take place in the developed world through sponsored pharmaceutical company research. The corresponding lack of research in developing countries results in two unmet needs related to cancer treatment in the developing world. First, recommended treatments do not reflect ethnic (genetic), cultural and resource differences between developed countries and developing countries that are not subject to clinical research. Second, there is little research conducted on those cancers that are primarily found in developing countries. Thus the ability to diagnose and treat these diseases is impaired. This general picture reflects today's situation globally, then it is critical to promote clinical research in developing countries mainly with training of all levels of research professionals (data managers, research nurses, etc.) in a local context, and training on identifying resources to fund research outside of pharmaceutical company sponsorship.Disclosure
E.L. Cazap: Leadership Position SLACOM, ASCO, UICC Consultant: Bayer; Schering Pharma Honoraria: Bayer; Bristol-Myers Squibb; Fresenius Research Funding: Poniard Pharmaceuticals; Daiichi Sankyo Pharma; Breast Cancer Research Foundation (BCRF).